


CASE REPORT ON AUTONOMIC NEUROPATHY INDUCED BY BORTEZOMIB

 $G\ Molas^1$, $A\ Manzaneque^1$, $B\ Tenas^1$, $C\ Noguera^1$, $L\ Lopez$ -Torres 1 , $F\ Vall$ -llover a^2 , $T\ Villalobos^2$, $J\ Nicolas^1$.

- 1- Pharmacy Department. Hospital Universitari Mutua de Terrassa, Spain.
- 2- Haematology Department. Hospital Universitari Mutua de Terrassa, Spain.

Peripheral neuropathy is one of the most common adverse reactions to bortezomib. However, bortezomib can much less frequently produce other nervous system alterations. We present the case of a patient undergoing bortezomib treatment for multiple myeloma (MM), who developed toxicity in form of autonomic neuropathy.




68 years old

Hypertension, dyslipidaemia and depressive syndrome



Diagnosed with Multiple
Myeloma (MM) in May 2023



Induction treatment D-VRd:

Daratumumab / Bortezomib / Lenalidomide / Dexamethasone

CYCLE 1 OF TREATMENT WITH D-VRd:

Excellent tollerance





Included in the home chemotherapy administration program



CYCLE 2 OF TREATMENT WITH D-VRd:



8th day: diarrhoea \rightarrow Hygienic-dietary recommendations

11th day (cumulative bortezomib dose: 16.8mg):

- Hypo-reactive
- Difficulty in speaking and standing
- Non-reactive pupils
- Skin pallor







DURING HOSPITALIZATION



- Hypotension (76/52mmHg)
- Dizziness
- Intolerance to standing
- Grade 2 diarrhoea

Tests performed:

- Echocardiography
- CT scan
- Cardiac magnetic resonance
- Myocardial scintigraphy
- Subcutaneous fat biopsy

Diagnoses ruled out:

- × Cardiac causes
- × Structural brain abnormalities
- × Amyloidiosis
- × Infectious origin

Final diagnosis:

✓ Vasovagal episodes secondary to autonomic neurological toxicity due to bortezomib

- Intensive fluid therapy was administered
- Progressive improvement was observed
- Patient was discharged on the sixth day of admission with the ability to walk without recurrence of symptoms
- Treatment for MM was resumed after 15 days without bortezomib.
- Bortezomib was not administered again, and the symptoms did not recur.

The reaction was classified as "probable" according to the Naranjo algorithm.

Autonomic neuropathic toxicity caused by bortezomib should be considered in the differential diagnosis of orthostatic hypotension in haematological patients. Home chemotherapy administration allows for early detection of toxicities and streamlines healthcare processes.

